(Date:5/15/2008)...erapy given in conjunction with cancer vaccines ma...mproving the effectiveness of this promising type ...hers in the Duke Comprehensive Cancer Center. , ...hat suppress immune function and we speculated tha... in conjunction with vaccines, which work by boost...
(Date:5/15/2008)...y 15 /PRNewswire-FirstCall/ -- Digital Power,Corpo...y announced its,financial results for the first qu...ed revenue of $3,169,000 for the quarter ended,Mar...for the same quarter,last year. An operating loss ...rted, compared to an operating profit of $25,000 f...
(Date:5/15/2008)...PRNewswire/ -- JumpStart Inc., the Northeast Ohio,...the growth of innovative,early-stage businesses an...,$350,000 in CerviLenz(TM), Inc. The Cleveland-bas...Drug Administration cleared medical,device that al...th in,pregnant women, which has been established b...
(Date:5/15/2008)...Clinton Promise Comprehensive Healthcare Plans, Lo...e, Private Funding, KIRKLAND, Wash., May 15 /PRNe...oduce healthcare reform? "Probably," says Cameron ...nced long term care insurance,agencies, LTC Financ...Clinton,s, or perhaps McCain,s -- cover all health...
Breaking Medicine News(10 mins):Health News:Chemotherapy might help cancer vaccines work 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2...azil government is up against giant drug manufactu...‘pricey’ anti-AIDS drug Efavirenz.According to the...as much as 1.59 US dollars for a 600mg pill when T...e. Negotiations between Merck and the Brazilian ...
...ry of Human Resource Development in collaboration ... launched an educational programme,// known as Ado...implemented by all the States and Union Territorie...imed at the following learning outcomes: (i) to ma...
... rice fields reverberate with the activities of fa...concern amongst the lot, for the climate// has not...s. Some farmers feel the weather has also turned c...inued undisturbed for generations, even in the fac...
...p of IT students here have developed a device that... or read//. Called 'E-Netra', it costs Rs.2,000-3,...and converts them into voice that can be heard thr... Right now it can only read text, but later it is...
Other Medicine News:Health News:Brazil Government In Contention With Merck Over Anti-AIDS Drug 2(Date:5/15/2008)... SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ ...ed that data from an ongoing Phase 1-2 clinical,tr...3100, will be presented,in an oral presentation at...SCO) Annual Meeting in Chicago., Session title:...e Cancer Session date and time: Monday, June 2 at...
(Date:5/15/2008)... MELBOURNE, Australia, May 15 /PRNewswire-Firs...ed that the abstract for its upcoming oral,present...American Society,of Clinical Oncology (ASCO) will ...ttp://www.asco.org ) from 9pm on Thursday 15 May (...I evaluation of CYT997, a novel,cytotoxic and vasc...
(Date:5/15/2008)... BRIDGEWATER, N.J., May 15 /PRNewswire-FirstCa...) announced today that findings from the,landmark ...ential therapy,for the treatment of patients with ...he risk of cardiovascular hospitalizations or deat...% (p=0.00000002), meeting the study,primary endpoi...
(Date:5/15/2008)... BOSTON, May 15 /- CenterWatch, a...ed on market research about clinical,trials, finds...ltiple EDC,(electronic data capture) systems. More...urvey indicated that they had been trained on thre...icated that the effectiveness of,their EDC trainin...
Breaking Medicine Technology:Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 2Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 3Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 4Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 5Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 6Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation 7CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence 2ARUP Laboratories CEO and Co Founder Announces Retirement 4658 1ARUP Laboratories CEO and Co Founder Announces Retirement 4658 2California Stem Cell Agency Exaggerated Its Role in Funding Key Research 1831 1California Stem Cell Agency Exaggerated Its Role in Funding Key Research 1831 2U of M researchers identify process that may help treat Parkinsons spinal cord injuries 17034 1U of M researchers identify process that may help treat Parkinsons spinal cord injuries 17034 2USP announces 2008 summer internship program participants 17031 1USP announces 2008 summer internship program participants 17031 2...harmaceuticals Inc.,(TSX: TLN) announced today tha...ial investigating ECO-4601 in advanced cancer,pati... American,Society of Clinical Oncology (ASCO) Annu...se escalation portion of the study, 14,patients (t...lioma), that had completed and not responded to th...
...res favorably with,the activity of mTOR inhibitors...Call/ - AEterna,Zentaris Inc. , a global biopharma...oncology, today announced that its partner,Keryx ...ase 1 and,Phase 2 results for perifosine, an oral ..., for the treatment of patients with,advanced sarc...
Other Medicine Technology:Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 2Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data,at ASCO 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products:Allergens, Food, Red PepperAllergens, Food, PimentoAllergens, Upper Respiratory Disease Profile, Region 17, Cascade Pacific Northwest (N.W. CA, Western OR and WA)Allergens, Upper Respiratory Disease Profile, Region 12, Arid Southwest (S.AZ, S.E. CA Desert)